Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
copper Cu 64-DOTA-A2DM
- Development stage
- Phase 1
- Lead developer
- City of Hope
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Copper Cu 64-DOTA-A2DM is a radiopharmaceutical diagnostic imaging agent developed by City of Hope Medical Center. It consists of the positron-emitting radioisotope copper-64 (64Cu) conjugated via the chelator DOTA to a modified antibody fragment (A2 scFv-Fc2 DM) that specifically targets Prostate Stem Cell Antigen (PSCA). PSCA is a cell surface protein highly expressed in pancreatic cancer and other malignancies but with limited expression in normal tissues. The agent is utilized in positron emission tomography (PET) to detect and image PSCA-expressing tumors, particularly in patients with locally advanced or metastatic pancreatic cancer. This imaging approach facilitates patient selection for PSCA-targeted therapies and allows for the non-invasive monitoring of disease status and treatment response.
- Other names
- 64Cu-DOTA-A2DM PET
02
Targets
PSCA (Prostate stem cell antigen)
Beyond the preview
Go deeper on copper Cu 64-DOTA-A2DM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on copper Cu 64-DOTA-A2DM.